The U.S. Food and Drug Administration replaces Dr. Tracy Beth Hoeg, who has been serving as acting director of the agency’s drug center, according to multiple reports. Hoeg, an FDA official who had been involved in reviewing the safety of widely used therapies, is stepping down from her role in the agency’s latest leadership changes. Outlets describe her work as including scrutiny of COVID-19 vaccines and antidepressants, among other treatments.
Reports state that Dr. Mike Davis will replace Hoeg as acting director of the FDA’s drug center. The changes are presented as part of broader personnel shake-ups within the FDA, though the accounts provided do not include detailed reasons for Hoeg’s removal or specific new responsibilities for Davis. The reports consistently identify Hoeg’s title and the general scope of her prior focus, and they agree on the identity of the incoming acting director. No sources in the provided excerpts offer information on whether the review activities referenced will continue under new leadership or how they may be altered.
